Among our cohort of 30 ROS1+NSCLC patients who received crizotinib treatment, the median PFS was 18.4 months, which was similar to the results of PROFILE 10015 and was longer than the PFS reported by Wu et al7 Of note, the ORR reported here was much higher than that previous reported in PROFILE 10015 and OO‐1201.7 Given that these previous studies did not breakout the clinical effect by line of crizotinib therapy, the higher ORR may contribute to all the patients in our study given crizotinib in the first‐line. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.